Sorafenib for the treatment of multiple myeloma.
Gentile M et al. Expert Opin Investig Drugs. 2016 Mar 21. [Epub ahead of print].

Model-based pharmacokinetic analysis of elotuzumab in patients with relapsed/refractory multiple myeloma.
Gibiansky L et al. J Pharmacokinet Pharmacodyn. 2016 Mar 18. [Epub ahead of print].

The prospects and promise of chimeric antigen receptor immunotherapy in multiple myeloma.
Rotolo A et al. Br J Haematol. 2016 Mar 8. doi: 10.1111/bjh.13976. [Epub ahead of print].

Reduction in C-reactive protein indicates successful targeting of the IL-1/IL-6 axis resulting in improved survival in early stage multiple myeloma.
Lust JA et al. Am J Hematol. 2016 Mar 6. doi: 10.1002/ajh.24352. [Epub ahead of print].

Management of Multiple Myeloma with Second-Generation Antibody-Drug Conjugates.
Robak P et al. BioDrugs. 2016 Feb 29. [Epub ahead of print].

Monoclonal antibodies targeting CD38 in hematological malignancies and beyond
van de Donk NW et al. Immunol Rev. 2016 Mar;270(1):95-112. doi: 10.1111/imr.12389.